Reliability of Autoantibodies Against a Tissue Transglutaminase Neo-Epitope for the Diagnosis of Pediatric Celiac Disease.

Background: This study aimed to assess the declared benefits of the new test using antibodies against tissue transglutaminase in complex with gliadin representing a neo-epitope in the IgA and IgG class of immunoglobulins compared with currently used tissue transglutaminase antibodies in the IgA class of immunoglobulins among children.

Methods: In the cross-sectional study (P1 study, n = 406) and two small-size prospective observational studies (P2 study, n = 59 and P3 study, n = 12), serum samples from all children were simultaneously tested for endomysial antibodies, IgA tissue transglutaminase antibodies, and antibodies against tissue transglutaminase in complex with gliadin in the IgA and IgG class of immunoglobulins. The exact McNemar test, Wilcoxon test, and Spearman's correlation coefficient were used to analyze the data.

Symptom positivity is essential for omitting biopsy in children with suspected celiac disease according to the new ESPGHAN guidelines.

The aim of this study was to assess the accuracy of serological tests in combination with clinical symptoms for diagnosing celiac disease (CD) according to the new proposed European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) criteria. We retrospectively assessed children and adolescents aged 16 months -19 years who were examined for suspicion of CD (n = 345). Evaluation of clinical symptoms and the presence of tissue transglutaminase (anti-TG-IgA) and endomysial antibodies (EMA-IgA) as well as intestinal biopsies was performed in all patients.